Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Eight RNAi-Related Patent Applications: Aug 14, 2008

Premium
Title: Detection of Small Nucleic Acids
 
Number: 20080187926
 
Filed: Oct. 30, 2007
 
Lead Inventor: James Dahlberg, Third Wave Technologies
 
The invention, the patent application’s abstract states, “relates to compositions and methods for the detection and characterization of interfering RNAs such as microRNAs … small interfering RNAs, and other short nucleic acid molecules. More particularly, the … invention relates to improved methods for the detection and quantitation of interfering RNA expression … [and] further provides for the detection of variants and types of miRNAs and siRNAs.”
 

 
Title: Methods for Gene Targeting
 
Number: 20080188001
 
Filed: Feb. 6, 2008
 
Inventor: Michael Paul Strathmann, CombiMatrix
 
The invention “provides methods for generating and characterizing gene-targeting events by using tags,” the patent application’s abstract states. “More specifically, the invention employs methods to enrich for cells that have undergone the desired targeting event.”
 

 
Title: Bioinformatically Detectable Group of Novel HIV Regulatory Genes and Uses Thereof
 
Number: 20080188428
 
Filed: Oct. 30, 2003
 
Inventor: Isaac Bentwich, Rosetta Genomics
 
According to the patent application’s abstract, the invention “relates to a group of novel viral RNA regulatory genes [called] … viral genomic address messenger genes or VGAM genes, and as viral genomic record or VGR genes. VGAM genes selectively inhibit translation of known host target genes and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an operon-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease,” the abstract adds. “Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes … comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes and for counteracting their activity.”
 

 
Title: RNA Interference-Mediated Inhibition of Hypoxia Inducible Factor 1 Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20080188430
 
Filed: Aug. 20, 2004
 
Lead Inventor: Nassim Usman, Sirna Therapeutics (Merck)
 
“This invention relates to compounds, compositions, and methods useful for modulating hypoxia inducible factor gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HIF1 gene expression and/or activity by RNA interference using small nucleic acid molecules.”
 

 
Title: Composition and Methods for siRNA Inhibition of Angiogenesis
 
Number: 20080188437
 
Filed: March 6, 2008
 
Lead Inventor: Michael Tolentino, Opko Health
 
The invention, the patent application’s abstract states, comprises “RNA interference using small interfering RNAs [that] are specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR [and can] inhibit expression of these genes. Diseases which involve angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age-related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.”
 

 
Title: siRNA Targeting DNA-Damage-Inducible Transcript 4
 
Number: 20080188647
 
Filed: July 24, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to DDIT4.”
 

 
Title: siRNA Targeting Human Hairless Protein
 
Number: 20080188648
 
Filed: July 24, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to HR.”
 

 
Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
 
Number: 20080188675
 
Filed: March 13, 2008
 
Lead Inventor: Tongqian Chen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.
 
“Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies … cholesterol, hormones …, dsRNA, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid … to relevant cells and/or tissues, such as in a subject or organism,” the abstract adds. “Such novel cationic lipids, microparticles, nanoparticles and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject, or organism.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.